Profile cover photo
Profile photo
BiondVax Pharmaceuticals Ltd
2 followers -
Developing a Universal Flu Vaccine
Developing a Universal Flu Vaccine

2 followers
About
Posts

Post has attachment
"As many as 646,000 people are dying globally from seasonal influenza each year"
Add a comment...

Post has attachment
BiondVax has signed a Clinical Trial Agreement (CTA) for a Phase 2 Trial in the U.S. with the NIH's +NIAID.
http://www.biondvax.com/2017/11/biondvax-and-nih-sign-clinical-trial-agreement-for-a-phase-2-trial-in-the-u-s-with-biondvaxs-universal-flu-vaccine/
Photo
Add a comment...

Post has attachment

Post has attachment

Post has attachment
A patent covering use of M-001, BiondVax's Universal #FluVaccine candidate, has been accepted in Australia. This same patent has has been filed in other jurisdictions and already been granted in the USA (http://www.biondvax.com/2016/01/biondvax-universal-flu-vaccine-receives-additional-us-patent/)

The patent is titled "“Multimeric Multiepitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines”
Photo
Add a comment...

Post has attachment
"BiondVax’s vaccine is designed to defend against these new potential pandemic viruses."

#BirdFlu #H5N6 #H5N8 #UniversalFluVaccine
Add a comment...

Post has attachment
BiondVax's #UniversalFluVaccine M-001 covered in Vaccine (journal)​

http://www.biondvax.com/science/scientific-publications/influenza-vaccine-research-vaccine-2016/

"...the vaccine is safe and able to elicit influenza-specific nonneutralizing antibodies and T cell responses in both young and older (65+) adults [50]. Moreover, M-001 was shown to prime antibody responses elicited by conventional TIV and increase the seroconversion rate induced by TIV [51]. Based on these observations, the capacity of M-001 to be a pandemic primer is further tested in the current phase IIb study…”
Add a comment...

Post has attachment

Post has attachment
* Professor Shai Ashkenazi Appointed to BiondVax’s Scientific Advisory Board *

An experienced clinician-researcher, Prof Ashkenazi has guided multiple vaccines through clinical and regulatory approval phases to market.

Welcome Prof. Ashkenazi to the BiondVax team!

http://www.biondvax.com/2016/09/professor-shai-ashkenazi-appointed-to-biondvaxs-scientific-advisory-board/
Add a comment...

Post has attachment
So just how much deadlier are Ebola and Zika than influenza?
Add a comment...
Wait while more posts are being loaded